CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC
DOI 10.1055/a-2150-4130
Bibliografische Angaben
Nachweis in CareLit
Autor:innenKatharina Deininger, Joel Niclas Raacke, Elham Yousefzadeh-Nowshahr, Cornelia Kropf-Sanchen, Bernd Muehling, Meinrad Beer, Gerhard Glatting, Ambros J. Beer, Wolfgang Thaiss
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe05/2023
Jahrgang / SeitenJg. 62 · S. 284-292
Kernaussage aus der Literatur
Abstract-Vorschau
Abstract Aim The aim of this study was to derive prognostic parameters from 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG-PET/CT) in patients with low-risk NSCLC and determine their prognostic value. Methods 81 (21 female, mean age 66 a) therapy-naive patients that underwent [18F]FDG-PET/CT before histologic confirmation of NSCLC with stadium I and II between 2008–2016 were included. A mean follow-up time of 58 months (…
Zitieren
Zitierempfehlung
Katharina Deininger, Joel Niclas Raacke, Elham Yousefzadeh-Nowshahr, Cornelia Kropf-Sanchen, Bernd Muehling, Meinrad Beer, Gerhard Glatting, Ambros J. Beer, Wolfgang Thaiss (2023) Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC. Nuklearmedizin - NuclearMedicine, 62 (05), 284-292. https://doi.org/10.1055/a-2150-4130
Mit CareLit weiterarbeiten